Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Public ClinicalTrials.gov record NCT06119217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients Not Previously Treated for Metastatic Pancreatic Adenocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metastatic disease and are eligible to receive gemcitabine and nab-paclitaxel chemotherapy as SOC.
Study identification
- NCT ID
- NCT06119217
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 194 participants
Conditions and interventions
Conditions
Interventions
- TTX-030, nab-paclitaxel and gemcitabine Combination Product
- TTX-030, budigalimab, nab-paclitaxel and gemcitabine Combination Product
- Nab-Paclitaxel and gemcitabine Combination Product
Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2024 (Actual)
- Primary completion
- Nov 17, 2025 (Actual)
- Completion
- Mar 6, 2026 (Actual)
- Last update posted
- May 13, 2026
2024 – 2026
United States locations
- U.S. sites
- 28
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Tucson | Arizona | 85704 | — |
| Investigative SIte | Hot Springs | Arkansas | 71913 | — |
| Investigative Site | Bakersfield | California | 93309 | — |
| Investigative Site | Fullerton | California | 92835 | — |
| Investigative Site | Los Angeles | California | 90095 | — |
| Investigative Site | Denver | Colorado | 80218 | — |
| Investigative Site | St. Petersburg | Florida | 33705 | — |
| Investigative Site | West Palm Beach | Florida | 33401 | — |
| Investigative Site | Atlanta | Georgia | 30318 | — |
| Investigative Site | Wichita | Kansas | 67214 | — |
| Investigative Site | Baton Rouge | Louisiana | 70809 | — |
| Investigative Site | Columbia | Maryland | 21044 | — |
| Investigative Site | Burnsville | Minnesota | 55337 | — |
| Investigative Site | Las Vegas | Nevada | 89119 | — |
| Investigative Site | Florham Park | New Jersey | 07932 | — |
| Investigative Site | Asheville | North Carolina | 28806 | — |
| Investigative Site | Columbus | Ohio | 43219 | — |
| Investigative Site | Eugene | Oregon | 97401 | — |
| Investigative Site | Portland | Oregon | 97239 | — |
| Investigative Site | Horsham | Pennsylvania | 19044 | — |
| Investigative Site | Austin | Texas | 78705 | — |
| Investigative Site | Dallas | Texas | 75246 | — |
| Investigative Site | San Antonio | Texas | 78258 | — |
| Investigative Site | Tyler | Texas | 75702 | — |
| Investigative Site | Arlington | Virginia | 22205 | — |
| Investigative Site | Norfolk | Virginia | 23502 | — |
| Investigative Site | Roanoke | Virginia | 24014 | — |
| Investigative Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06119217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06119217 live on ClinicalTrials.gov.